Literature DB >> 22336606

[Study on incidence of HIV infection among heroin addicts receiving methadone maintenance treatment in Dehong prefecture, Yunnan province].

Song Duan1, Yue-cheng Yang, Jing Han, Shun-sheng Yang, Ying-bo Yang, Yu-cun Long, Guo-qiang Li, Jin-song Yin, Li-fen Xiang, Run-hua Ye, Jie Gao, Ren-hai Tang, Lin Pang, Ke-ming Rou, Zun-you Wu, Na He.   

Abstract

OBJECTIVE: To determine the incidence and risk factors of HIV infection among heroin addicts receiving methadone maintenance treatment (MMT) in Dehong prefecture, Yunnan province.
METHODS: All heroin addicts who were HIV negative at the initiation of MMT in June 2005 and through June 2011, in Dehong prefecture were included in the cohort analysis. HIV incidence was calculated and related risk factors determined by using Cox proportional hazard regression model.
RESULTS: A total of 3154 MMT clinic attendants were qualified for this cohort study. By June 2011, 1023 (32.4%) of them had never received any follow-up HIV testing so were thus referred as loss to follow-up. The other 2131 (67.6%) members had received at least one follow-up HIV testing and were observed for a total of 4615.86 person-years. During the period, 22 new HIV infections or seroconverters were identified, making the overall HIV incidence as 0.48/100 person-years. The HIV incidence was higher among those who were unemployed, never married, self-reported being injecting drug users (IDUs) and HCV positive at entry into the MMT program. None of those who were always negative on follow-up-urine-testing of morphine was discovered as HIV newly infected during the follow-up period. Data from multiple regression analysis under Cox proportional hazard model indicated that after controlling for confounding variables, non-IDUs at the entry point for the MMT program, were less likely to be HIV newly-infected or seroconverted than IDUs (HR = 0.29, 95%CI: 0.11 - 0.76).
CONCLUSION: MMT program in Dehong prefecture was demonstrated to be fairly effective in reducing HIV transmission through drug use. Those HIV negative attendants at the MMT clinic who were IDUs or keep using drugs during the treatment, were at higher risk of HIV seroconvertion. More efforts were needed to improve the follow-up and HIV testing programs for the MMT clinic attendants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22336606

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  5 in total

1.  HIV epidemic among drug users in China: 1995-2011.

Authors:  Lan Wang; Wei Guo; Dongmin Li; Zhengwei Ding; Jennifer M McGoogan; Ning Wang; Zunyou Wu; Lu Wang
Journal:  Addiction       Date:  2015-01       Impact factor: 6.526

2.  HIV seroconversion and risk factors among drug users receiving methadone maintenance treatment in China: A qualitative study.

Authors:  Changhe Wang; Cynthia X Shi; Bo Zhang; Hong Chen; Hua Wang; Nanci Zhang; Keming Rou; Xiaobin Cao; Wei Luo; Zunyou Wu
Journal:  Drug Alcohol Depend       Date:  2016-08-21       Impact factor: 4.492

3.  Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study.

Authors:  Xia Zou; Li Ling; Lei Zhang
Journal:  BMJ Open       Date:  2015-08-21       Impact factor: 2.692

4.  Spatial distribution of HIV, HCV, and co-infections among drug users in the southwestern border areas of China (2004-2014): a cohort study of a national methadone maintenance treatment program.

Authors:  Mingli Li; Rongjian Li; Zhiyong Shen; Chunying Li; Nengxiu Liang; Zhenren Peng; Wenbo Huang; Chongwei He; Feng Zhong; Xianyan Tang; Guanghua Lan
Journal:  BMC Public Health       Date:  2017-09-30       Impact factor: 3.295

5.  Spatiotemporal clusters of HIV/AIDS infections caused by drug use and heterosexual contact in Ruili city, China 1989-2016.

Authors:  Li Jiang; Zhoulin Li; Jin Huang; Bang Liu; Yingbo Yang; Lanzhu Lin; Chengbo Wang; Ximei Xie; Xia Peng; Wen Xu; Hong Li
Journal:  BMC Infect Dis       Date:  2019-10-30       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.